Eisai GmbH
Pharmaceutical Companies · Frankfurt am Main
Eisai GmbH is the German subsidiary of japanischen Pharmaunternehmens Eisai Co, based in Frankfurt am Main. Key areas: Neurologie (Alzheimer, Epilepsie) und Onkologie.
Content in German
The detailed company information on this page is provided in the original German language. You can use your browser's built-in translation feature to view it in English.
Right-click on the page and select "Translate to English" or use the translation icon in your browser's address bar.
Eisai GmbH Address & Contact
Company profile
1941
Founded
11.000+ (global)
Employees
Eisai GmbH at a Glance
Eisai GmbH is the German subsidiary of the Japanese pharmaceutical company Eisai Co., Ltd., one of Japan's leading pharmaceutical companies. The German branch is located in Frankfurt am Main and specializes in neurological and oncological therapies. The company's history in Germany is closely linked to Eisai's global vision of providing patients and their families with a better quality of life through innovative therapeutic approaches. Through continuous research and development, Eisai GmbH aims to advance medical progress and meet the needs of physicians and patients.
Neurological and Oncological Focus Areas
Eisai is known in Germany for products used in the treatment of epilepsy, including Fycompa and Inovelon, which are distinguished by their different mechanisms of action and are tailored to individual patient needs. A remarkable feature of epilepsy therapy is the integration of innovative approaches developed using the latest technologies. In addition, Alzheimer's research is one of Eisai's core fields. Medications like Aricept are used for the symptomatic treatment of mild to moderate Alzheimer’s disease and are a central part of the portfolio.
In the oncology sector, Eisai markets Lenvatinib (Lenvima) for the treatment of thyroid, liver, and renal cell carcinomas, as well as Eribulin (Halaven) for metastatic breast cancer. These therapies have proven significant in cancer treatment and are approved in many European countries. The development and marketing of such products is the result of years of research that Eisai has conducted in close collaboration with leading research institutions and clinics.
Regulatory Classification and Responsibilities
Eisai GmbH is subject to the strict guidelines of the European Medicines Agency (EMA) as well as the German Federal Institute for Drugs and Medical Devices (BfArM). These regulatory authorities ensure that all products offered in Germany meet the highest quality standards and are safe for patients. This includes both clinical research and ongoing monitoring of already approved medicines. Compliance with these regulatory requirements is a central part of Eisai’s corporate strategy to take on both clinical and societal responsibility.
Location Frankfurt am Main
Frankfurt, as a European financial and pharmaceutical hub, is a strategically important location for Eisai. The city not only offers excellent transportation connections that foster international partnerships but is also home to numerous medical institutions and research centers. From Frankfurt, Eisai GmbH coordinates collaboration with neurologists, oncologists, and university hospitals in the German market. Through local networks and regional partnerships, Eisai has established important contacts that help accelerate the development of therapies. The site also serves as a basis for marketing and sales strategies in Germany, tailored to the specific needs of the market. A top priority is close collaboration with medical professionals.
Another aspect of Eisai's regional significance is its commitment to raising awareness about neurological and oncological diseases. Through numerous initiatives and events, Eisai promotes the exchange between science and practice and increases awareness of these conditions in society.
More pharmaceutical companies in Germany | pharmaceutical companies in Frankfurt | pharmaceutical companies in Hesse
```Frequently asked questions about Eisai GmbH
What does Eisai GmbH do?
Eisai GmbH is a pharmaceutical company, the u.a. Mittel gegen fortgeschrittenen and metastasierten Schilddrüsenkrebs and fortgeschrittenen, not operierbaren Leberkrebs herausgibt. Krebs the Gebärmutterschleimhaut and Brustkrebs and Mittel gegen Epilepsie are weitere Anwendungsgebiete.
More Pharmaceutical Companies in Frankfurt am Main
Pharmaceutical Companies in Germany
Related areas in healthcare
Pharmaceutical Companies by location
About Pharmaceutical Companies
Germany is one of the world's leading pharmaceutical nations, home to more than 1,000 pharmaceutical businesses employing approximately 130,000 people (vfa 2023). Companies operating in this sector develop, manufacture and distribute medicines across the entire value chain, from early-stage research and clinical trials through to market authorisation and commercial distribution. In Germany, every manufacturer of medicinal products must hold a manufacturing authorisation (Herstellungserlaubnis) issued under Section 13 of the AMG (Arzneimittelgesetz, Germany's Medicinal Products Act). Medicines may only be placed on the market after receiving approval from either BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte, Germany's Federal Institute for Drugs and Medical Devices, broadly comparable to the FDA in the United States or the MHRA in the United Kingdom) or the European Medicines Agency (EMA) via the centralised procedure. All manufacturing sites are subject to regular GMP (Good Manufacturing Practice) inspections carried out by the competent pharmaceutical supervisory authority of the relevant German federal state. The sector covers prescription-only medicines (Rx), non-prescription OTC products, generics, biosimilars and active pharmaceutical ingredients (APIs). This directory lists pharmaceutical manufacturers, marketers and licence holders across all German federal states with full contact details, addresses and phone numbers.
Germany's Pharmaceutical Industry
Germany is consistently ranked among the top five pharmaceutical markets worldwide, generating annual revenues exceeding EUR 50 billion and accounting for the largest share of pharmaceutical production in continental Europe. The industry is represented by two major associations: vfa (Verband Forschender Arzneimittelhersteller), which represents research-based companies, and BAH (Bundesverband der Arzneimittel-Hersteller), which represents the broader manufacturer base including OTC and self-medication products. German pharmaceutical companies cover the full spectrum from global innovator corporations and mid-sized specialty manufacturers to generic producers and biotech firms. The country is a world leader in active pharmaceutical ingredient (API) production, biologics manufacturing and pharmaceutical chemistry. Key therapeutic areas of strength include oncology, cardiovascular medicine, immunology, neuroscience and rare diseases. Germany also serves as a significant export hub, with pharmaceutical products among the country's leading export categories. The sector benefits from a highly skilled workforce, world-class university research institutions and a dense network of research hospitals (Universitätsklinika) that facilitate clinical trial activity.
Regulatory Framework: BfArM, EMA and the AMG
The legal foundation for pharmaceutical activity in Germany is the Arzneimittelgesetz (AMG, German Medicinal Products Act), which regulates the authorisation, manufacture, import, distribution, labelling and pharmacovigilance of medicinal products. For English-speaking readers unfamiliar with the German regulatory landscape: BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is the national competent authority responsible for approving medicines marketed only in Germany, supervising narcotics, and maintaining the pharmacovigilance database. BfArM is a higher federal authority (Bundesoberbehörde) subordinate to the Federal Ministry of Health (Bundesministerium für Gesundheit). For medicines approved via the centralised EU procedure, the European Medicines Agency (EMA) grants a single marketing authorisation valid in all 27 EU member states. Germany is also home to the Paul-Ehrlich-Institut (PEI), a second federal authority that specifically handles biological medicines including vaccines, blood products and gene therapy products. Manufacturing sites are inspected by state-level pharmaceutical supervisory authorities (Landesbehörden) to verify GMP compliance, with findings entered into the EudraGMDP database operated by the EMA.
Regional Pharmaceutical Clusters in Germany
Germany's pharmaceutical industry is geographically distributed across several major regional clusters. The Rhine-Main area around Frankfurt and Leverkusen in North Rhine-Westphalia is home to some of Germany's largest pharmaceutical sites, including facilities belonging to global corporations with long histories in German chemistry and pharmaceuticals. Bavaria (particularly Munich, Penzberg and Marburg) is a second major hub, especially strong in biotechnology and biologics production. Baden-Württemberg, including cities such as Mannheim, Heidelberg and Biberach an der Riss, is home to several significant research-based manufacturers. Hamburg and the northern German region have a cluster of specialty and generic manufacturers. Berlin has a growing biotech scene connected to its research universities and the Charité hospital. Hesse is notable for its proximity to Frankfurt's logistics infrastructure and several major API manufacturers. Smaller but significant clusters exist in Saxony (Leipzig, Dresden) and Lower Saxony, benefiting from proximity to university research centres and historically established chemical industry sites.
Drug Classes and Product Segments
German pharmaceutical companies cover all major drug classes. Prescription (Rx) products account for the largest share of revenue; generics manufacturers such as Stada, ratiopharm (Teva) and Hexal produce chemically equivalent alternatives after patent expiry, significantly reducing costs for the healthcare system. Biologics and biosimilars are gaining ground rapidly: monoclonal antibodies, insulin analogues and recombinant growth factors require specialised biotech manufacturing facilities. OTC products (over-the-counter), i.e. medicines available without a prescription, represent a multi-billion-euro market served by companies such as Bayer Consumer Health, Stada and Klosterfrau. Homeopathic preparations, herbal medicines and dietary supplements form further regulated segments. Digitalisation is increasingly shaping the sector: Digital Health Applications (DiGA) have been reimbursable since 2020, and AI-assisted drug development is significantly shortening time-to-market.
What does a pharmaceutical company do?
Pharmaceutical companies develop, produce and distribute medicines. They cover the entire value chain from research and clinical trials through to market launch and distribution. In Germany, they are supervised by BfArM (the Federal Institute for Drugs and Medical Devices, comparable to the FDA or MHRA).
How are pharmaceutical companies regulated in Germany?
Pharmaceutical companies in Germany must hold a manufacturing authorisation under Section 13 of the AMG (German Medicinal Products Act). All authorised medicines require approval from either BfArM or the European Medicines Agency (EMA). Regular GMP (Good Manufacturing Practice) inspections ensure quality standards are maintained.
Where can I find contact details for pharmaceutical companies in Germany?
Industry associations such as vfa (Association of Research-Based Pharmaceutical Companies) and BPI (Federal Association of the German Pharmaceutical Industry) maintain member directories. Many companies also list their key contacts directly on their websites. Sanoliste provides a searchable directory of pharmaceutical companies in Germany sorted by federal state and city.
How many pharmaceutical companies are there in Germany?
Germany is home to more than 1,000 pharmaceutical companies employing approximately 130,000 people, according to vfa (the Association of Research-Based Pharmaceutical Companies) 2023 data. The sector includes multinational corporations, mid-sized specialty firms, generic manufacturers and biotech startups.
What is BfArM and what does it regulate?
BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is Germany's Federal Institute for Drugs and Medical Devices. It is a higher federal authority within the portfolio of the Federal Ministry of Health and is responsible for approving medicines for the German market, monitoring drug safety (pharmacovigilance), regulating narcotics and controlled substances, and overseeing medical devices in Germany. It is broadly comparable to the FDA in the United States or the MHRA in the United Kingdom.
What is the difference between BfArM approval and EMA approval?
Medicines in Germany can be approved through two main routes. BfArM grants national marketing authorisations valid in Germany, or decentralised and mutual recognition procedure approvals valid in multiple EU states. The EMA (European Medicines Agency) grants centralised marketing authorisations valid in all 27 EU member states simultaneously, typically used for innovative biologic medicines, oncology drugs and products for rare diseases.
What does GMP mean in the context of German pharmaceutical manufacturing?
GMP stands for Good Manufacturing Practice. In Germany and the EU, GMP compliance is a legal requirement for all pharmaceutical manufacturers under the AMG and the EU GMP Guidelines (EudraLex Volume 4). GMP covers all aspects of production including premises, equipment, personnel qualification, process validation, documentation and quality control. Compliance is verified by regular inspections from the competent state pharmaceutical supervisory authority.